Insmed Incorporated (NASDAQ:INSM) Receives Consensus Recommendation of “Buy” from Analysts

Insmed Incorporated (NASDAQ:INSM) has received an average rating of “Buy” from the sixteen analysts that are currently covering the firm, MarketBeat Ratings reports. Sixteen analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have covered the stock in the last year is $82.73.

Several equities research analysts recently issued reports on the company. The Goldman Sachs Group increased their price objective on Insmed from $74.00 to $102.00 and gave the stock a “buy” rating in a research note on Wednesday, July 10th. StockNews.com lowered shares of Insmed from a “hold” rating to a “sell” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. boosted their price objective on shares of Insmed from $72.00 to $74.00 and gave the company an “overweight” rating in a research report on Thursday, October 3rd. Stifel Nicolaus increased their target price on shares of Insmed from $74.00 to $88.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, TD Cowen boosted their price target on shares of Insmed from $75.00 to $98.00 and gave the company a “buy” rating in a report on Friday, August 9th.

Insmed Stock Down 0.9 %

INSM stock opened at $70.30 on Thursday. The company has a debt-to-equity ratio of 25.05, a current ratio of 2.71 and a quick ratio of 2.53. The firm has a market capitalization of $10.45 billion, a P/E ratio of -13.44 and a beta of 1.11. Insmed has a 52-week low of $21.92 and a 52-week high of $80.53. The company’s 50 day simple moving average is $73.61 and its 200-day simple moving average is $60.87.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The business had revenue of $90.34 million for the quarter, compared to the consensus estimate of $87.95 million. The firm’s revenue for the quarter was up 17.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.78) earnings per share. As a group, equities research analysts anticipate that Insmed will post -5.41 EPS for the current year.

Insiders Place Their Bets

In related news, insider Martina M.D. Flammer sold 13,436 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $74.92, for a total value of $1,006,625.12. Following the transaction, the insider now directly owns 106,134 shares of the company’s stock, valued at approximately $7,951,559.28. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Martina M.D. Flammer sold 13,436 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total value of $1,006,625.12. Following the transaction, the insider now directly owns 106,134 shares in the company, valued at approximately $7,951,559.28. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the transaction, the insider now directly owns 100,100 shares of the company’s stock, valued at approximately $7,157,150. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 78,882 shares of company stock valued at $5,765,446 over the last quarter. Insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Clearbridge Investments LLC bought a new stake in shares of Insmed in the first quarter valued at approximately $25,242,000. Kennedy Capital Management LLC acquired a new position in Insmed during the 1st quarter valued at $267,000. Susquehanna Fundamental Investments LLC bought a new stake in Insmed in the 1st quarter valued at $4,515,000. Russell Investments Group Ltd. grew its position in Insmed by 15,915.2% in the 1st quarter. Russell Investments Group Ltd. now owns 22,101 shares of the biopharmaceutical company’s stock worth $600,000 after purchasing an additional 21,963 shares during the last quarter. Finally, Requisite Capital Management LLC bought a new position in shares of Insmed during the 1st quarter worth about $678,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.